Farwell Kelly D, Shahmirzadi Layla, El-Khechen Dima, Powis Zöe, Chao Elizabeth C, Tippin Davis Brigette, Baxter Ruth M, Zeng Wenqi, Mroske Cameron, Parra Melissa C, Gandomi Stephanie K, Lu Ira, Li Xiang, Lu Hong, Lu Hsiao-Mei, Salvador David, Ruble David, Lao Monica, Fischbach Soren, Wen Jennifer, Lee Shela, Elliott Aaron, Dunlop Charles L M, Tang Sha
Ambry Genetics, Aliso Viejo, California, USA.
1] Ambry Genetics, Aliso Viejo, California, USA [2] Division of Genetics and Metabolism, Department of Pediatrics, University of California, Irvine, Irvine, California, USA.
Genet Med. 2015 Jul;17(7):578-86. doi: 10.1038/gim.2014.154. Epub 2014 Nov 13.
Diagnostic exome sequencing was immediately successful in diagnosing patients in whom traditional technologies were uninformative. Herein, we provide the results from the first 500 probands referred to a clinical laboratory for diagnostic exome sequencing.
Family-based exome sequencing included whole-exome sequencing followed by family inheritance-based model filtering, comprehensive medical review, familial cosegregation analysis, and analysis of novel genes.
A positive or likely positive result in a characterized gene was identified in 30% of patients (152/500). A novel gene finding was identified in 7.5% of patients (31/416). The highest diagnostic rates were observed among patients with ataxia, multiple congenital anomalies, and epilepsy (44, 36, and 35%, respectively). Twenty-three percent of positive findings were within genes characterized within the past 2 years. The diagnostic rate was significantly higher among families undergoing a trio (37%) as compared with a singleton (21%) whole-exome testing strategy.
Overall, we present results from the largest clinical cohort of diagnostic exome sequencing cases to date. These data demonstrate the utility of family-based exome sequencing and analysis to obtain the highest reported detection rate in an unselected clinical cohort, illustrating the utility of diagnostic exome sequencing as a transformative technology for the molecular diagnosis of genetic disease.
诊断性外显子组测序在诊断传统技术无法提供信息的患者方面立竿见影。在此,我们报告了前500例转诊至临床实验室进行诊断性外显子组测序的先证者的结果。
基于家系的外显子组测序包括全外显子组测序,随后进行基于家系遗传模式的筛选、全面的医学评估、家族共分离分析以及新基因分析。
30%的患者(152/500)在已明确的基因中获得阳性或可能阳性结果。7.5%的患者(31/416)发现了新的基因。共济失调、多发先天性畸形和癫痫患者的诊断率最高(分别为44%、36%和35%)。23%的阳性结果出现在过去两年内已明确的基因中。与单人全外显子检测策略相比,采用三联体检测策略的家庭诊断率显著更高(37%比21%)。
总体而言,我们展示了迄今为止最大规模的诊断性外显子组测序临床队列的结果。这些数据证明了基于家系的外显子组测序和分析在未选择的临床队列中获得最高报道检出率的效用,说明了诊断性外显子组测序作为遗传疾病分子诊断的变革性技术的效用。